Therapeutic Asset Ratings
374 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Interferon Beta 1
Relapsing-Remitting Multiple Sclerosis
Novartis Pharmaceuticals
P2
CCC
(53)
jsb462
Prostate Cancer
Novartis Pharmaceuticals
P2
CCC
(53)
jsb462
Prostatic Cancer, Castration-Resistant
Novartis Pharmaceuticals
P2
CCC
(53)
Osimertinib
Advanced Solid Tumors Which Are cMET-dependent
Novartis Pharmaceuticals
P2
CCC
(53)
Rapcabtagene Autoleucel
Diffuse Scleroderma
Novartis Pharmaceuticals
P2
CCC
(53)
Ribociclib
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
Novartis Pharmaceuticals
P2
CCC
(53)
Spartalizumab
Renal Cell Carcinoma
Novartis Pharmaceuticals
P2
CCC
(53)
vhb937
Amyotrophic Lateral Sclerosis
Novartis Pharmaceuticals
P2
CCC
(53)
VIPIVOTIDE TETRAXETAN
Prostatic Cancer, Castration-Resistant
Novartis Pharmaceuticals
P2
CCC
(53)
Pembrolizumab
Nasopharyngeal Carcinoma
Novartis Pharmaceuticals
P1/2
CCC
(53)
Spartalizumab
Non-Small Cell Lung Carcinoma
Novartis Pharmaceuticals
P2
CCC
(52)
Zoladex
Melanoma
Novartis Pharmaceuticals
P2
CCC
(52)
MIDAZOLAM
Acute Myeloid Leukemia
Novartis Pharmaceuticals
P1/2
CCC
(52)
ltp001
Idiopathic Pulmonary Fibrosis
Novartis Pharmaceuticals
P2
CCC
(51)
vhb937
Alzheimer Disease
Novartis Pharmaceuticals
P2
CCC
(51)
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 1.BETA.) (HUMAN CLONE ACZ885 HEAVY CHAIN V REGION)
Cognitive Disorder
Novartis Pharmaceuticals
P2
CCC
(50)
Epirubicin
Nasopharyngeal Carcinoma
Novartis Pharmaceuticals
P1/2
CCC
(50)
FULVESTRANT
Advanced HR+/HER2- Breast Cancer
Novartis Pharmaceuticals
P1/2
CCC
(50)
Letrozole
Advanced HR+/HER2- Breast Cancer
Novartis Pharmaceuticals
P1/2
CCC
(50)
egf816
Non-Small Cell Lung Carcinoma
Novartis Pharmaceuticals
P2
CCC
(49)
Axicabtagene Ciloleucel
Acute Lymphoblastic Leukemia
Novartis Pharmaceuticals
P2
CCC
(48)
Capmatinib
Advanced Solid Tumors Which Are cMET-dependent
Novartis Pharmaceuticals
P2
CCC
(48)
gxv813
Schizophrenia
Novartis Pharmaceuticals
P2
CCC
(48)
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 1.BETA.) (HUMAN CLONE ACZ885 HEAVY CHAIN V REGION)
Alzheimer Disease
Novartis Pharmaceuticals
P2
CCC
(48)
Ociperlimab
Triple-Negative Breast Carcinoma
Novartis Pharmaceuticals
P2
CCC
(48)
Showing 126 to 150 of 374 assets
Previous
Page 6 of 15
Next